---
title: Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB
nct_id: NCT01953783
overall_status: COMPLETED
phase: PHASE1
sponsor: Millennium Pharmaceuticals, Inc.
study_type: INTERVENTIONAL
primary_condition: Advanced Solid Tumors
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01953783.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01953783"
ct_last_update_post_date: 2020-08-26
last_seen_at: "2026-05-12T07:06:20.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB

**Official Title:** A Phase 1 Study of [ 14 C]-Ixazomib to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphoma

**NCT ID:** [NCT01953783](https://clinicaltrials.gov/study/NCT01953783)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 7
- **Lead Sponsor:** Millennium Pharmaceuticals, Inc.
- **Conditions:** Advanced Solid Tumors, Lymphoma
- **Start Date:** 2014-03-19
- **Completion Date:** 2016-02-09
- **CT.gov Last Update:** 2020-08-26

## Brief Summary

This is a phase 1, 2-part, open-label study in 4 to 6 pharmacokinetic-evaluable participants with advanced solid tumors or lymphoma.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

Each participant must meet all of the following inclusion criteria to be enrolled in the study:

* 18 years or older
* Histologic or cytologic diagnosis of advanced or metastatic solid tumor or lymphoma for which no standard, curative, or life-prolonging therapies exist or are effective
* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
* Female participants who are postmenopausal for at least 1 year OR are surgically sterile OR if of childbearing potential, agree to practice 2 effective methods of contraception at the same time during the entire study through 90 days after the last dose of study drug OR agree to practice true abstinence
* Male participants who agree to practice effective barrier contraception during the entire study and through 90 days after the last dose of study drug OR agree to practice true abstinence
* Voluntary written consent
* Suitable venous access for the conduct of blood sampling
* Recovered from the reversible effects of prior anticancer therapy

Exclusion Criteria:

Participants meeting any of the following exclusion criteria are not to be enrolled in the study:

* Female participants who are lactating or breastfeeding or have a positive serum pregnancy test
* Serious medical or psychiatric illness that could interfere with the study
* Treatment with any investigational products or radiotherapy within 21 days before the first dose of study drug
* Peripheral neuropathy greater than (\>) Grade 2
* Systemic treatment with strong and moderate inhibitors of CYP1A2, strong and moderate inhibitors of CYP3A, or clinically significant CYP3A inducers or use of Ginkgo biloba or St. John's wort within 14 days before the first dose of study drug
* Symptomatic brain metastasis. Participants with brain metastases: must have stable neurologic status following local therapy (surgery or radiation) for at least 2 weeks after completion of the definitive therapy; and must be without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events (AEs)
* Ongoing treatment with corticosteroids
* Major surgery within the 14 days preceding the first dose of study drug
* Infection requiring systemic intravenous antibiotic therapy or other serious infection within 14 days before the first dose of study drug
* Life-threatening illness unrelated to cancer
* Known hepatitis B surface antigen -positive, or known or suspected active hepatitis C infection or human immunodeficiency virus (HIV) positive
* Diagnosed or treated for another malignancy within 2 years before the first dose, OR previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
* Any cardiovascular condition specified in the study protocol
* Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of IXAZOMIB
* History of urinary and/or fecal incontinence
* Inability to comply with study procedures or visit schedule including the requirement for inpatient confinement
```

## Arms

- **IXAZOMIB** (EXPERIMENTAL) — Part A: Participants will receive a single dose of 4.1-milligram (mg) \[14C\]-IXAZOMIB oral solution containing approximately 500-nCurie (nCi) of total radioactivity on Day 1 and remain at the clinic for 8 days. On Days 14 and 21, participants may be administered a single 4.0-mg capsule of IXAZOMIB. Participants will return to the clinic in the evening before Days 14, 21, 28, and 35 for a 24-hour overnight clinic visit.

Part B: Eligible participants from Part A may continue into Part B once they have completed their Day 35 assessments in Part A. Participants may receive IXAZOMIB capsules administered orally at a dose of 4.0-mg once weekly on Days 1, 8, and 15 of 28-day cycles. Participants will continue in this study until disease progression or unacceptable toxicity.

## Interventions

- **IXAZOMIB** (DRUG) — Part A: Ixazomib 4.1 mg containing approximately 500-nCi \[14C\]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21.

Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity.

## Primary Outcomes

- **Part A: Cmax: Maximum Observed Plasma Concentration for Ixazomib** _(time frame: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose)_ — Maximum observed plasma concentration (Cmax) is the peak plasma concentration of ixazomib, obtained directly from the plasma concentration-time curve.
- **Part A: Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Ixazomib** _(time frame: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose)_ — Time to reach the maximum observed plasma concentration (Cmax), equal to time (hours) to Cmax of ixazomib after administration, obtained directly from the plasma concentration-time curve.
- **Part A: AUC(0-312): Area Under the Plasma Concentration-time Curve From Time 0 to 312 Hrs Post-dose for Ixazomib** _(time frame: Day 1 of Part A pre-dose and at multiple timepoints (up to 312 hrs) post-dose)_ — AUC(0-312) is a measure of the area under the plasma concentration time-curve from time zero to 312 hrs post-dose for ixazomib.
- **Part A: Cmax: Maximum Observed Plasma Concentration of TRA** _(time frame: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose)_ — Maximum observed plasma concentration (Cmax) of TRA is the peak plasma concentration of TRA, obtained directly from the plasma TRA concentration-time curve.
- **Part A: Tmax: Time to Reach the Cmax for TRA** _(time frame: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose)_ — Time to reach the maximum observed plasma concentration (Cmax) for TRA, equal to time (hours) to Cmax for TRA after administration, obtained directly from the plasma TRA concentration-time curve.
- **Part A: AUC(0-816): Area Under the Plasma Concentration-time Curve From Time 0 to 816 Hrs Post-dose for TRA** _(time frame: Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose)_ — AUC(0-816) is a measure of the area under the plasma concentration time-curve from time zero to 816 hrs post-dose for TRA.
- **Part A: Cmax: Maximum Observed Whole Blood Concentration of TRA** _(time frame: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose)_ — Maximum observed whole blood concentration (Cmax) of a TRA is the peak whole blood concentration of TRA, obtained directly from the whole blood TRA concentration-time curve.
- **Part A: Tmax: Time to Reach the Maximum Observed Whole Blood Concentration (Cmax) for TRA** _(time frame: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose)_ — Time to reach the maximum observed whole blood concentration (Cmax) for TRA, equal to time (hours) to Cmax for TRA after administration, obtained directly from the whole blood TRA concentration-time curve.
- **Part A: AUC(0-816): Area Under the Whole Blood Concentration-time Curve From Time 0 to 816 Hrs Post-dose for TRA** _(time frame: Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose)_ — AUC(0-816) is a measure of the area under the whole blood concentration time-curve from time zero to 816 hrs post-dose for TRA.
- **Part A: Cumulative Percentage of Ixazomib Dose Recovered in the Urine** _(time frame: Day 1 of Part A from 0 to pre-dose and at multiple timepoints (up to 168 hrs) post-dose)_ — Percentage of the ixazomib dose excreted unchanged in the urine from 0 to 168 hrs post-dose.
- **Part A: Cumulative Percentage of the Total Radioactivity Dose Excreted in Feces** _(time frame: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose)_ — Percentage of the TRA dose excreted in feces from Day 1 to Day 35 of Part A
- **Part A: Cumulative Percentage of the Total Radioactivity Dose Excreted in Urine** _(time frame: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose)_ — Percentage of the TRA dose excreted in urine from Day 1 to Day 35 of Part A.
- **Part A: Renal Clearance of Ixazomib** _(time frame: Day 1 pre-dose and at multiple timepoints (up to Day 14) post-dose)_ — Renal clearance is the volume of plasma from which ixazomib is completely removed by the kidney in a given amount of time, calculated as the amount of ixazomib excreted in the urine divided by the area under the plasma ixazomib concentration-time curve.

## Secondary Outcomes

- **Ixazomib and Metabolites as Percent of Total Radioactivity in Plasma** _(time frame: Day 1 pre-dose and at multiple time points (up to 816 hrs) post-dose)_
- **Ixazomib and Metabolites as Percent of Total Dose Administered in Urine** _(time frame: Day 1 pre-dose and at multiple time points (up to Day 35) post-dose)_
- **Ixazomib and Metabolites as Percent of Total Dose Administered in Feces** _(time frame: Day 1 pre-dose and at multiple time points (up to Day 35) post-dose)_
- **Number of Participants Reporting One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)** _(time frame: Baseline up to Cycle 5 Day 45)_
- **Number of Participants With TEAEs Related to Investigations System Organ Class for Laboratory Values** _(time frame: Baseline up to Cycle 5 Day 45)_
- **Number of Participants With TEAEs Related to Vital Signs** _(time frame: Baseline up to Cycle 5 Day 25)_

## Locations (1)

- Cleveland, Ohio, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.|cleveland|ohio|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01953783.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01953783*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*